Slides
Page 1
1 ATOMO DIAGNOSTICS FY26 AGM PRESENTATION 5 NOVEMBER 2026
Page 2
2 This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on information available as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision. Reliance should not be placed on the information or opinions contained in this presentation. An investor must not act on the basis of any matter contained in this presentation but should make its own assessment of Atomo as part of its own investigations. This presentation has been provided for general information purposes only. It does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Atomo, nor does it constitute financial product advice or take into account any individual’s investment objectives, taxation situation, financial situation or needs. Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, neither Atomo, nor any of its officers, directors, employees and agents, nor any other person, accepts any responsibility or liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it. This disclaimer also extends to all and any information and opinions contained in, and any omissions from, any other written or oral communications transmitted or otherwise made available to the recipient in connection with the opportunity outlined in this presentation and no representation or warranty is made in respect of such information. The information presented in this presentation is subject to change without notice and Atomo does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation. The cover image is illustrative only. This presentation may contain certain forward-looking statements that are based on Atomo’s beliefs, assumptions and expectations and on information currently available to Atomo management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Atomo to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding present and future business strategies and the business, economic and competitive environment in which they operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance, and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward-looking statements or other forecast. To the full extent permitted by law, Atomo and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation). ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) DISCLAIMER ASX: AT1
Page 3
3 OUR MISSION Put the user experience at the centre of diagnostics—expanding equitable and affordable access to accurate diagnosis and a seamless pathway to treatment. HOW WE WORK IMPACT Commercialise products that matter in point-of-care settings. INNOVATION Turn creative thinking into practical solutions. INTEGRITY Act with honesty and fairness in everything we do. COLLABORATION Work as one global team. EXCELLENCE Be recognised as experts in the field. Five values translate Atomo’s purpose into how the company innovates, partners and delivers. OUR PURPOSE: Empowering healthier lives through fast, accurate, point of care testing PURPOSE-LED INNOVATION BUILT ON CORE VALUES ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) 3
Page 4
4ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) Commercial-stage diagnostics company with a growing pipeline of proprietary and OEM partnerships WHO IS ATOMO? WHAT BUSINESSES DO WE HAVE? COMMERCIAL STAGE DIAGNOSTIC COMPANY with approved professional and self-test point-of-care products sold across global markets. DIFFERENTIATED TECHNOLOGY Patented all-in-one blood collection solutions designed for superior usability, reliability and performance in decentralised testing. PROVEN COMMERCIAL TRACTION HIV GEN 3 | +21% FY26 YoY 5m+ tests supplied across 30+ countries. ATOMO PROPRIETARY PRODUCTS Blood-based rapid tests sold globally through professional and self-test channels. IN MARKET HIV Gen 3 franchise GROWING PIPELINE Gen 4 HIV · Active Syphilis · Liver / ALT POINT-OF-CARE TECHNOLOGIES | OEM Integrated all-in-one and modular devices that help partners improve the usability and performance of blood-based tests. FEBRIDX® DRIVES GROWTH OEM revenue +209% FY26 YoY | 215 live US sites in Q1FY27 PARTNER PIPELINE Pregnancy commercial · Ferritin and pre-hospital stroke in validation WHO IS ATOMO AND WHAT DO WE DO?
Page 5
5ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) SOLUTIONS THAT DELIVER Issues with Standard Multi-Component Test Kits Advantages of Atomo Devices Initial solutions focused on transforming usability in the lateral flow market Next generation POCT devices that provide superior usability and performance
Page 6
6ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) Future of Point of Care & Rapid Testing [8] EASY TO USE SPEED OF RESULTS EASY TO OBTAIN & AFFORDABLE Simple to use products providing reliability and usability in decentralised settings Rapid results with a high degree of accuracy Accessibility online and increasingly through retail and via healthcare professionals Report - Comparative usability analysis of two rapid diagnostic self-test kits [9] ASX: AT1 Focus on ease of use, speed of results and affordability ASX: A1 ATOMO PLATFORM DRIVING ADOPTION OF RAPID TESTING
Page 7
7ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) Each platform simplifies capillary blood collection and delivery; the key difference is how it integrates with the test cassette. PASCAL Integrated all-in-one platform MOST INTEGRATED CONFIGURATION • Built-in, auto-retracting safety lancet • Precise button-activated buffer delivery • Interlocked steps help reduce user error • 99% concordance between professional and non- professional users PRIMARY FIT POINT OF CARE + SELF-TEST GALILEO Streamlined all-in-one platform SIMPLIFIED BLOOD HANDLING • Built-in, auto-retracting safety lancet • Precise blood collection and delivery • Patient-delivered buffer creates assay flexibility PRIMARY FIT POINT OF CARE + SELF-TEST FLOREY Modular clip-on usability upgrade LOW-DISRUPTION CASSETTE UPGRADE • Clips onto an existing blood-based cassette • Adds precise button-activated buffer delivery • Cassette remains readable by a validated reader PRIMARY FIT EXISTING COMMERCIAL TESTS SOLUTIONS THAT DELIVER Atomo offers three blood-based platforms driven by the market requirements 7
Page 8
8ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) ASX: AT1 Atomo’s audited QMS supports registrations achieved directly and with partners ASX: A1 GLOBAL QUALITY & REGULATORY STRENGTH QUALITY FOUNDATION External scrutiny Regularly audited by multiple tier-one national regulators and the World Health Organization. Measurable quality objectives Business and product objectives are set at the levels required to meet product requirements. IVDR-ready governance QMS compliant with IVDR requirements for Class III and IV products. CERTIFICATES & REGULATORY EVIDENCE GLOBAL REGULATORY FOOTPRINT ATOMO — LISTED MANUFACTURER HIV SELF TEST TGA · Australia WHO PQ · LMIC | CE Mark · UK & Europe PARTNER REGISTRATIONS PREGNANCY TEST CE Mark · UK & Europe | ANVISA · Brazil LUMOS DIAGNOSTICS’ FEBRIDX FDA 510(k) + CLIA waiver · USA CE Mark · UK & Europe | TGA · Australia Health Canada · Canada TGA WHO PQ FDA CE MARK ANVISA HEALTH CANADA BSI / QMS TGA WHO PQ CE SAHPRA FUTURE FOCUS • MDSAP • ACTIVE SYPHILIS — TGA / IVDR • GEN 4 HIV — TGA / IVDR SYPHILIS / GEN 4 HIV – Future Filings TGA · Australia CE Mark · UK & Europe
Page 9
9ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) TWO PROVEN ENGINES FOR COMMERCIAL GROWTH Commercial-stage diagnostics company pairing an established HIV franchise with a proven OEM platform ATOMO PROPRIETARY PRODUCT FRANCHISE +21% FY26 HIV SALES GROWTH | YOY HIV GEN 3 DEMONSTRATES ATOMO’S ABILITY TO BUILD AND SCALE ITS OWN PRODUCTS 5m+ tests supplied across 30+ countries, with growth led by international supply and ANZ pharmacy channels. OEM PARTNERSHIP BUSINESS +209% FY26 OEM REVENUE GROWTH | YOY FEBRIDX® SHOWS THE POWER OF THE OEM PARTNERSHIP MODEL Device supply increased 224% in 1Q27 YOY. Proven and growing revenue bases validate the two scalable paths to diversified growth
Page 10
ASX: AT1 Commercial products fund a broader portfolio progressing through validation, development and feasibility ATOMO PROPRIETARY PRODUCT PIPELINE ASX: AT1 Proprietary portfolio spans established revenue products and new tests targeting decentralised professional and self-test markets. PRODUCT / APPLICATION FEASIBILITY STUDY DEVELOPMENT VALIDATION COMMERCIAL HIV GEN 3 HIV screening / self-test COMMERCIAL HIV GEN 4 Antibody + p24 antigen DEVELOPMENT ACTIVE SYPHILIS Active vs treated infection VALIDATION LIVER / ALT Liver health screening DEVELOPMENT HCV Hepatitis C virus FEASIBILITY HBV Hepatitis B virus FEASIBILITY 10ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
Page 11
OVERVIEW OF ATOMO'S GEN 3 HIV SELF-TEST ASX: AT1 Integrated, highly accurate self-testing platform with established market adoption and expanding retail and public-health channels 11ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) TEST DIFFERENTIATION 15 MINUTES Integrated, blood-based rapid diagnostic test designed for convenient, private and discreet self- testing. SIMPLIFIES THE USER JOURNEY All-in-one components and interlocked steps reduce procedural complexity and help mitigate common user errors. PRODUCT + MARKET PROOF 99.6% SENSITIVITY identifies HIV-positive samples 99.6% SPECIFICITY identifies HIV-negative samples 5M+ TESTS SUPPLIED to markets across more than 30 countries Performance published by Atomo; reach and supply figures from company materials. COMMERCIAL MOMENTUM AUSTRALIAN MARKET LEADER Across public and private channels, supported by national mail-out and vending-machine programs. RETAIL EXPANSION Chemist Warehouse in Australia and New Zealand, plus Tesco and Boots in the UK. PUBLIC-HEALTH PROCUREMENT Free-to-user access programs and government purchasing are emerging as long-term growth drivers.
Page 12
ACTIVE SYPHILIS TRANSFERS TO MANUFACTURING ASX: AT1 Program remains on schedule, with regulator engagement beginning and launch targeted within 18–24 months 12ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) TEST DIFFERENTIATION 15 MINUTES Rapid lateral flow test for home- based and healthcare-practitioner- guided self-testing. ADDRESSES A KEY TESTING GAP Designed to detect infectious syphilis and distinguish active cases from previously treated cases. EARLY CLINICAL PERFORMANCE 100% SENSITIVITY against active syphilis samples by clinical history 99% SPECIFICITY against never-infected patients 93% SPECIFICITY against previously treated cases with clinical history Early clinical testing; results reported by clinical history. PROGRAM ON SCHEDULE TRANSFER COMPLETE Test-strip manufacturing moved from Burnet Institute in Melbourne to Cape Town for clinical- trial production builds. NEXT: CLINICAL TRIALS Trials expected to commence early next year. REGULATORY + LAUNCH Engagement planned with TGA, FDA and BSI; commercial launch targeted within 18–24 months.
Page 13
ASX: AT1 Global licence, development and supply agreement with Innovation Scientific GEN 4 HIV PARTNERSHIP OPENS A NEW COMMERCIAL PATH ASX: AT1 THE MOU AGREEMENT Atomo to receive a global licence to commercialise a rapid Gen 4 HIV assay in its Galileo cassette. Feasibility testing complete. The partnership now moves into final analytical/clinical studiesand regulatory preparation. Parties to negotiate final Supply Agreement and License over next four months. WHO DOES WHAT INNOVATION SCIENTIFIC — Complete final assay development — Run analytical and clinical studies with Atomo — Integrate Galileo sub-assemblies with the strip and buffer for finished supply ATOMO — Hold the global assay licence and act as legal manufacturer — Lead IVDR and TGA registration, launch and commercialisation COMMERCIAL PATH 18 MONTHS Planned IVDR and TGA registration window 24 MONTHS Target timing for commercial launch A$1.16bn HIV global rapid-test kit market STRATEGIC FIT Extends Atomo’s Gen 3 HIV + Active Syphilis portfolio; own-pipeline revenue is targeted from late FY2028. Manufacture and supply Galileo sub-assemblies— Source: Future Market Insights, 2026; Market Glass, Inc., 2026; MarketsandMarkets, 2025 13ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
Page 14
ALT LIVER TEST: LIVER-INJURY INSIGHT AT THE POINT OF CARE ASX: AT1 A proven ALT assay on Atomo’s Pascal platform creates multiple clinical, pharmaceutical and public-health pathways 14ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) TEST PROPOSITION ALT A key marker of liver damage used in diagnosis, treatment evaluation and disease monitoring. DECENTRALISED TESTING Fingerstick blood testing on the Pascal platform enables rapid liver- injury assessment at point of care and at home. DEVELOPMENT + PERFORMANCE WORLDWIDE LICENCE Burnet Institute assay; Atomo is the listed manufacturer and finished-test supplier Development is substantially complete; diagnostic performance has been established. BROAD COMMERCIAL UTILITY DILI MONITORING Pharmaceutical and clinical-trial monitoring for drug-induced liver injury. HEPATITIS MANAGEMENT Supports treatment decisions and ongoing monitoring in hepatitis B and C. LIVER-DISEASE SCREENING Potential screening pathways in fatty-liver and alcohol-related liver disease. Test shows good correlation (R2 = 0.9089) between fingerprick blood and venous blood The validation set gave AUC 0.94 performance distinguishing normal from abnormal ALT at 40 IU/L PERFORMANCE
Page 15
ASX: AT1 Atomo technology enables partner assays to move from technical validation into commercial supply at scale OEM PARTNER PIPELINE ASX: AT1 OEM pipeline focused on professional point-of-care markets and scalable partner supply. PRODUCT / APPLICATION FEASIBILITY DEVELOPMENT VALIDATION COMMERCIAL FEBRIDX® Lumos · acute respiratory infection COMMERCIAL FERRITIN Chromacare · iron deficiency VALIDATION BRAIN DISEASE Upfront · pre-hospital triage VALIDATION Atomo technology platforms support multiple partner assays—creating recurring device-supply opportunities as programs progress. PREGNANCY NG Biotech · early pregnancy detection COMMERCIAL 15ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
Page 16
ASX: AT1FEBRIDX®: FINGERSTICK TO 10-MINUTE ANTIBIOTIC DECISION AID ASX: AT1Lumos’ CLIA-waived test combines dual host-response biomarkers with Atomo’s integrated Pascal platform RAPID RESPIRATORY TRIAGE A rapid, instrument-free point-of-care test that helps distinguish bacterial infection from non-bacterial causes—supporting more confident antibiotic decisions. PRODUCT + COMMERCIAL OVERVIEW FebriDx pairs Lumos’ MxA + CRP host-response assay with Atomo’s Pascal cassette for a simple, portable fingerstick workflow. DIFFERENTIATE Dual MxA + CRP biomarkers help separate bacterial infection from non- bacterial etiology. DECIDE IN 10 A visual result after 10 minutes supports treatment decisions during the initial visit. SCALE IN THE US FDA CLIA waiver enables use at waived sites; Pascal delivered >99% trained/untrained concordance. A$1.9m FY26 Atomo FebriDx orders—approximately 9× FY25—supporting recurring Pascal demand. 16ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
Page 17
ATOMO OEM PERFORMANCE | FY26 YEAR-ON-YEAR +209% OEM SALES REVENUE +224% GROWTH IN DEVICES SUPPLIED US FEBRIDX® ADOPTION | LUMOS-REPORTED 215 LIVE US SITES September 2026 +26.5% 170 in July → 215 in September 405 sites under evaluation (350 in July) March 2026 FDA CLIA waiver expanded eligible US testing settings. OEM Momentum Flu-season inventory build fuels triple-digit revenue and device-volume growth. Strong YOY growth driven by Lumos Diagnostics’ FebriDx PASCAL OEM REVENUE PERFORMANCE ASX: AT1 17ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
Page 18
ASX: AT1TWO BLOOD-BASED TESTS EXPAND PASCAL PLATFORM ASX: AT1 NG Biotech pregnancy and Chromacare ferritin programs pair partner assays with an integrated fingerstick Sources: NG Biotech Professional Tests and Self-Tests; Chromacare Labs ferritin test; Atomo Diagnostics Pascal and partner materials. Accessed 23 Oct 2026. NG BIOTECH | BLOOD PREGNANCY CHROMACARE | FERRITIN NG Biotech’s hCG assay and Atomo’s all-in-one Pascal platform support both professional and self-testing settings. Chromacare’s quantitative ferritin assay is being integrated into Pascal for professional and at-home iron- deficiency testing. 5 MIN QUALITATIVE RESULT 10 µL FINGERSTICK SAMPLE 10 mIU/mL DETECTION LIMIT NG Biotech reports 100% sensitivity and specificity. 10 MIN QUANTITATIVE RESULT APP-GUIDED READ, STORE + TRACK PASCAL INTEGRATED BLOOD HANDLING Results can be tracked over time and shared with healthcare providers. 2 routes to market: professional testing + NG PRECISION+ consumer self-test. A$170k initial order supports product validation and regulatory registration. 18ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
Page 19
ASX: AT1 Upfront’s biomarker assay moves into Atomo’s technology platform UPFRONT + ATOMO PARTNER ON NEXT -GENERATION TEST ASX: AT1 LVTwo A rapid blood-based brain-disease test designed for use before hospital arrival— helping emergency teams triage suspected stroke or other brain-disease patients sooner. PARTNERSHIP ANNOUNCEMENT Atomo and Upfront announce partnership forUpfront’s next-generation test in Atomo’s device. DETECT Proprietary biomarker targets proteins associated with brain disease. DEPLOY Atomo hand-held devices combine blood collection, sample transfer and buffer delivery. DECIDE EARLIER Designed for pre-hospital use to support faster routing and treatment decisions. 9,000 Atomo sub-assemblies supplied for validation and verification activities to date 19ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
Page 20
FY 2026 FINANCIALS
Page 21
21ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) FY26 – PROFIT & LOSS AUD FY26 ($m) FY25 ($m) (%) Revenue 5.33 3.79 41% Cost of sales (3.45) (1.87) Gross Profit 1.88 1.92 (2%) Gross Margin 35% 51% Other income 2.24 1.52 47% Employee benefits expense (2.88) (3.26) 12% Foreign exchanges gains/(losses) (0.04) (0.01) (300%) Research and development costs (0.76) (0.62) (23%) Professional fees expense (0.49) (0.95) 48% Inventory obsolescence expense (0.12) (0.13) 8% Other expenses (1.89) (1.85) (2%) Underlying EBITDA (2.06) (3.38) 39% Revenue grew strongly and the underlying EBITDA loss narrowed by 39% * Amounts in A$m; YoY compares FY26 with FY25 REVENUE $5.33m FY25 $3.79m +41% YoY GROSS MARGIN 35% FY25 51% -16 pts YoY UNDERLYING EBITDA ($2.06m) FY25 ($3.38m) 39% improvement
Page 22
22ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) FY26 – BALANCE SHEET AUD FY26 ($m) FY25 ($m) Cash and cash equivalents 3.71 3.22 Trade and other receivables 3.22 1.69 Inventories 1.97 1.65 Property, plant and equipment 0.34 0.89 Intangible assets 1.22 1.64 Other assets 0.36 0.18 Total assets 10.82 9.27 Trade and other payables 1.68 1.02 Other liabilities 1.43 1.28 Total liabilities 3.11 2.30 Net Assets 7.71 6.97 FY26 closed with $3.71m in cash, $10.66m in assets and no bank debt * Amounts in A$m; June 2026 audited actuals CASH $3.71m available liquidity TOTAL ASSETS $10.66m at June 2026 NO DEBT $0 bank borrowings
Page 23
23ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) FY26 CASHFLOW A$m 0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 Strong cash generation from sales, grants, and fundraising activities TOTAL CASH RECEIPTS $10.2m $4.6m customer receipts plus R&D rebate, CRC-P grant and capital TOTAL CASH PAYMENTS $9.7m $4.1m stock purchases $5.6m operating expenses YEAR-END CASH $3.7m at 30 June 2026 no debt
Page 24
Revenue Operating Discipline EBITDA Productive Assets FY25 Revenue A$3.8M ✓ Atomo is seeing strong momentum in its established revenue channels including HIV Testing and Pascal OEM ✓ Expansion of customer base across new partners for Pascal and an expanded Atomo test product pipeline FY26 Revenue A$5.3M +40% GROWTH ✓ Capital focus on new test portfolio development / commercialisation – Syphilis and Liver ✓ Non-dilutive funding grants (Syphilis) and selective licensing of proven assets (Liver) used to support lower-cost development and go to market -5 -4.5 -4 -3.5 -3 -2.5 -2 -1.5 -1 -0.5 0 FY24 FY25 FY26 A$(m) Historical EBITDA ✓ EBITDA – continued trend towards breakeven as existing revenue channels grow and product offerings expand ✓ Debt free balance sheet ✓ Atomo validating a second-generation blister machine and high-cavity mould tooling to support expansion of capacity and improve economies of scale and margins ASX: AT1 FINANCIAL SUMMARY 24ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) FY2026 was a transitional year, showing strong and sustainable revenue growth with improving EBITDA
Page 25
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) 25 FY26 Scale the core. Improve the margins. Expand the pipeline. Atomo’s priorities align commercial growth with manufacturing scale, disciplined cash management and the development of new finished tests. Point-of-care and self-testing solutions designed around simple, integrated blood collection. 01 HIV MARKET EXPANSION Grow established sales channels and secure new territory distribution partners. 02 PORTFOLIO EXPANSION Advance finished tests beyond HIV, including Liver and blood pregnancy opportunities. 03 SYPHILIS & GEN 4 HIV DEVELOPMENT Progress clinical and regulatory work for syphilis and Gen 4 HIV. 04 OPERATIONS & MARGINS Scale Pascal output and improve margins through in-housing and economies of scale. 05 CASH DISCIPLINE Maintain close control of operating costs and the use of cash. 06 PLATFORM ADOPTION Add Pascal OEM customers and progress Florey with an initial customer. STRATEGIC IMPERATIVES FOR FY2027 Executing priorities focused on revenue growth, portfolio expansion, and scalable operations
Page 26
26ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) BUILDING A STRONGER BASE FOR SCALABLE GROWTH Commercial momentum is funding a broader product pipeline and a more diversified revenue base $5.33m FY26 REVENUE | +41% YoY HIV franchise +21% YoY OEM revenue +209% YoY HIV FRANCHISE LEADS COMMERCIAL TRACTION HIV sales increased 21% year on year, led by international supply and ANZ pharmacy and public health channels. FEBRIDX® SHOWS THE POWER OF THE OEM MODEL OEM revenue reached $2.2m, up 209% year on year, while device supply increased 224%. DIVERSIFICATION BUILDS OVER TIME Commercial HIV, pregnancy, and FebriDx® provide the commercial base as the proprietary pipeline and OEM programs in syphilis, Gen 4 HIV, stroke, ferritin, and earlier-stage assays advance. A stronger HIV franchise and scalable OEM model support a broader, more diversified growth platform over time.